DEXCOM INC
Nasdaq: DXCM·San Diego, California·CIK 0001093557
- Price
- $81.61
- Base IV
- $33.70
Valuation snapshot
At $81.61, the price is above even our bull case of $50.72.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $33.70
- 41% of the price · range $21.04–$50.72
- Price vs base case
- 142% above
- $81.61 against $33.70
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $21.04 to bull $50.72. Values per share.
Price against each value
- Bear case
- $21.04
- Price 288% above
- No growth
- …
- —
- Base case
- $33.70
- Price 142% above
What does Dexcom do?
Dexcom provides continuous glucose monitoring systems and over-the-counter biosensors to help patients and clinicians manage diabetes and metabolic health through real-time glucose tracking.
It brought in $5.1B of sales in the 12 months to Sep 2026.
Led by Jacob S. (Jake) Leach, President and Chief Executive Officer since 2026. DexCom, Inc. Form 10-K for fiscal year 2025 (signed by Jacob S. Leach, President and Chief Executive Officer)
- Industry
- Healthcare
- Based in
- San Diego, California
- Trades on
- Nasdaq as DXCM
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 19¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 37¢ of every dollar.
- Making what it sells37¢
- Research and development12¢
- Sales, marketing and admin28¢
- Tax5¢
- Left as profit19¢
- Interest and other income came back in+1¢
Who pays Dexcom, and for what?
Dexcom designs and sells continuous glucose monitoring systems that track glucose throughout the day for people managing diabetes and metabolic health. It earns most of its revenue from disposable sensors, plus reusable transmitters and receivers.
Its products are used by patients, caregivers and clinicians; sales reach customers through distributors and direct channels, while many patients rely on government programs or private insurers for coverage.
Disposable sensors and reusable hardware
100%The company reports revenue from disposable sensors and reusable transmitters and receivers together; it does not give a separate revenue figure for either category.
Where its work physically happens, beyond headquarters:
- Batu Kawan manufacturing facility — Batu Kawan, Malaysia. This operating CGM manufacturing facility is one of Dexcom’s two primary production sites and supports global supply growth.
- Mesa manufacturing facility — Mesa, United States. Mesa is one of Dexcom’s two primary operating manufacturing sites for its continuous glucose monitoring products.
- Athenry manufacturing facility — Athenry, Ireland. Dexcom says this facility, under construction in its latest 10-K, is expected to add substantial manufacturing capacity.
How is the business doing?
Sales grew from $1.9B in 2020 to $4.7B in 2025, about 19% a year.
Running the business leaves about 24¢ of each sales dollar as operating profit, up from 16¢ in 2020.
After paying for its upkeep and new investment, it had $1.1B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Dexcom says it exists to help people take control of their health through biosensing technology.
“Empowering People to Take Control of Health”
Who is responsible for the plan?
- Jacob S. (Jake) LeachPresident and Chief Executive Officer
Leads Dexcom as President and CEO and is its principal executive officer. Dexcom's revenue comes mainly from its continuous glucose monitoring (CGM) systems, and the CEO is responsible for that business as a whole.
- Jon ColemanExecutive Vice President and Chief Commercial Officer
Oversees Dexcom's commercial organization as Chief Commercial Officer. The commercial organization is responsible for selling Dexcom's CGM systems, which generate the company's product revenue.
- Peter SimpsonExecutive Vice President and Chief Technology Officer
Leads Dexcom's technology vision and its innovation strategy for CGM products. Dexcom's sensor technology is the core of the CGM products the company sells.
Roles checked November 13, 2026.
What management says it is working on now:
Expand access and use
Management is working to broaden coverage and reach more people with diabetes, including people with Type 2 diabetes who do not use insulin, and to grow internationally.
Dexcom 2026 Investor Day presentationMove customers to longer-wear sensors
Management expects its 15-day sensor platform to become the basis of its product range over time, with customer transitions occurring gradually.
Dexcom 2026 Investor Day presentationDevelop future products and digital tools
Dexcom plans to improve sensor performance and convenience, build connected products, and develop software insights using glucose data and predictive tools.
DexCom, Inc. 2025 Form 10-K, Items 1 and 7Strengthen manufacturing and margins
Management is expanding production capacity and seeking manufacturing efficiencies while continuing to invest in research, clinical evidence and new markets.
Dexcom Q2 2026 Earnings CallSupport connected diabetes care
Dexcom continues to work with insulin delivery and consumer technology partners to connect its glucose systems with their products and services.
DexCom, Inc. 2025 Form 10-K, Item 1
- Organic revenue growth, Every year through 2030
- At least 10% each year
- DexCom, Inc. Form 8-K, Investor Day financial targets
- Non-GAAP operating profit margin, By 2030
- 29%–30%
- DexCom, Inc. Form 8-K, Investor Day financial targets
What's changing right now?
Growth is slowing. In Q3 2026 it sold 11% more than a year earlier. The year before, quarters averaged 16%.
Its operating margin is wider than a year ago: 24¢ per sales dollar, against 20¢.
Since Oct 2026 the share price has risen 2%, from $79.93 to $81.61.
Recently
October 29, 2026
Quarterly revenue growth, year over year changed to 11.2%
Dexcom Q3 2026 earnings releaseOctober 29, 2026
GAAP operating margin, quarterly changed to 24.3%
Dexcom Q3 2026 earnings releaseDecember 31, 2025
Annual GAAP Gross Margin changed to 60.1%
DexCom FY2025 Form 10-K Item 8
Coming up
Contracting begins 2027; payment changes from January 1, 2028
Medicare competitive bidding for CGMs
CMS plans to begin contracting for CGM suppliers in 2027, with payment changes expected to take effect in 2028. Dexcom expects lower Medicare reimbursement under the program.
DexCom, Inc. 2025 Form 10-K, Items 1 and 1ALate 2026
Ireland manufacturing facility
Management said the facility is being prepared for commercial production, which it expects to begin later in 2026.
Dexcom Q2 2026 Earnings CallBy the end of 2026
Transition from G6 to newer systems
Dexcom expects to transition G6 customers to G7 and G7 15 Day sensor systems, and phase out the previous Dexcom ONE system.
DexCom, Inc. 2025 Form 10-K, Item 1Results announced July 2026; future effects uncertain
Type 2 non-insulin CGM results
Dexcom reported positive results from its CONNECT study of CGM use among people with Type 2 diabetes who do not use insulin, a result that may support broader awareness and use.
Dexcom Reports Second Quarter 2026 Financial Results
Our own estimate moved too: the base case went from $40.05 to $33.70 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Reimbursement and pricing changes
Many customers depend on insurance or government coverage. Dexcom expects Medicare reimbursement to decrease beginning in 2028 under competitive bidding, which could also put pressure on prices and revenue.
From the company's own filingsWould hit how fast sales growDexCom, Inc. 2025 Form 10-K, Item 1A
Competition
Dexcom competes with established glucose-monitoring companies and newer entrants. New products, lower prices or broader wellness-device offerings could make it harder to attract or retain users.
From the company's own filingsWould hit how fast sales growDexCom, Inc. 2025 Form 10-K, Items 1 and 1A
Manufacturing and quality
Dexcom must scale production while meeting quality requirements. The company received an FDA warning letter in 2025; further compliance problems or supply interruptions could delay or restrict product sales.
From the company's own filingsWould hit how fast sales growDexCom, Inc. 2025 Form 10-K, Items 1 and 1A
Product development and adoption
New products and expanded uses may take longer than expected to develop, receive regulatory clearance or gain acceptance among patients, clinicians and insurers. Delays or weak adoption could limit growth.
From the company's own filingsWould hit how fast sales growDexCom, Inc. 2025 Form 10-K, Item 1A
Single-source suppliers
Some important components come from single suppliers. If a supplier cannot provide enough parts at the required quality or cost, production and deliveries could be affected.
From the company's own filingsWould hit how fast sales growDexCom, Inc. 2025 Form 10-K, Item 1
Coverage and patient affordability
Coverage rules can be restrictive and vary by insurer and location. If patients lose coverage or face higher out-of-pocket costs, fewer may use Dexcom products.
From the company's own filingsWould hit how fast sales growDexCom, Inc. 2025 Form 10-K, Item 1A
International revenue fell short of expectations in Q3 2026.
From our researchWould hit how fast sales growZacks: Dexcom Q3
Gross margin guidance was held at about 64%, below Q3's 65.1%, which limits the gross-margin tailwind.
From our researchWould hit how much of each sale it keepsFinimize: Dexcom lifted 2026 outlook
Is it a good business?
From 2016 to 2025 it earned between -28% and 24% on the capital invested in it, a median of 8%. Its cost of capital in the latest valuation is 10.4%; returns were above it in 3 of the 10 years.
From 2016 to 2025 it earned between -23% and 32% on its shareholders' equity, a median of 14%.
Over 10 years its operating margin ranged from 18¢ to 20¢ per sales dollar, a median of 12¢. Gross margin ran from 60¢ to 69¢.
Cost of capital 10.4%
It bought back shares: the count fell 5.9% in a year, so each remaining share owns a slightly bigger slice.
It owes $333.3M more than it holds in cash, about 0.3 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $81.61. Our put its value between $21.04 and $50.72, with $33.70 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $21.04
This scenario assumes Dexcom's sales growth keeps slowing from about 15% early in 2026 to low single digits as competitors push prices down, with profits staying near today's levels instead of improving.
Base case, $33.70
This scenario assumes Dexcom keeps growing at roughly 10% a year, slowing gently from its mid-teens pace, while its profits per dollar of sales improve modestly from recent levels.
Bull case, $50.72
This scenario assumes wider insurance coverage for people with type 2 diabetes lifts Dexcom's growth back into the low teens and that it keeps becoming more profitable, building on its recovery since early 2025.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 142%
For Dexcom to be worth today's $81.61, sales would need to grow about 31.6% a year. We assume 8.7%. Over the last 5 years, sales grew 17.1% a year.
Or, if sales grow 8.7% as we assume, the price works with a profit margin of 64.4% (we assume 27.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 31.6% a year?
Try your own numbersWe're moderately sure of this range: it scores 61 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $33.70 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average8.7%
- Operating margin27.0%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$33.70 -58.7%


